www.modernhealthcare.com

www.modernhealthcare.com
Share

www.modernhealthcare.com

 •  October 3

Not-for-profit and public hospitals are reining back their spending as they cope with rising drug prices and proposed cuts to the 340B program that continue to batter their margins. The gap between growth in not-for-profit and public providers' revenues and supply costs widened between 2015 and 2016, according to a report from Moody's Investors...

www.modernhealthcare.com

 •  September 23

MOUNTAIN VIEW, Ark.—Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year. Berry couldn't talk. Her face was drooping on one side. Her eyes couldn't focus. "She was basically unresponsive," Langston recalled. Berry, 78, was having a severe ischemic stroke. Each...

www.modernhealthcare.com

 •  September 16

The Food and Drug Administration this week is holding a public hearing on how risk assessments are conducted on new drugs. The agency is under immense pressure to reduce review and approval times of drugs in order to lower costs but also ensure medications are safe before they go to market. In 2014, the FDA implemented a more structured approach to...

The Senate overwhelmingly passed bipartisan legislation Thursday that reauthorizes U.S. Food and Drug Administration's ability to collect user fees from drug and device makers. The FDA user-fee agreements, which are renegotiated every five years with the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, fund nearly...

Health systems can expect drug prices to increase by 7.61% next year, largely due to the surging prices of branded, specialty medications, a group purchasing organization said Tuesday. Vizient said in its drug pricing forecast that it's seen a spike in purchases for products not offered on its contract, most of which are patented, branded...

More consolidation among healthcare distributors and pharmacy benefit managers has led to higher drug prices, according to a new article. The major players in both the distribution market and the PBM sector dominate their markets, the article published Monday in the Journal of the American Medical Association said. As the firms grew, prices for...

Drugmakers and providers say the newest proposal to change the way drugs are paid for under Medicare Part B is likely dead in the water. The Medicare Payment Advisory Commission Thursday voted 15-0 to recommend that Congress enact new drug reimbursement laws through several proposals that would decrease Medicare spending by as much as $750 million...

Three EpiPen users sued Mylan Monday over the injection's rising drug prices, claiming the company engaged in a racketeering sales scheme that inflated EpiPen's price. The proposed class-action lawsuit alleges Mylan's agreements with pharmacy benefit managers amount to illegal kickbacks. The plaintiffs claim that Mylan paid PBMs – including Express...

www.modernhealthcare.com

 •  February 14

With less than a week to go before the CMS unveils a new database describing payments made by industry to doctors and teaching hospitals, anxiety is high for the many people and organizations with their reputations on the line. The Open Payments Program database is a requirement of the Physician Payments Sunshine Act, a provision in the Affordable...

www.modernhealthcare.com

 •  February 14

What's in a name? A lot, according to groups battling over whether biosimilar pharmaceutical products should be allowed to use the same nonproprietary name as branded products. In March, in its first approval of a biosimilar product, the Food and Drug Administration designated the Sandoz product Zarxio with the placeholder nonproprietary name...